English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The study included 125 patients (90 women and 25 men) with various rheumatic diseases receiving GCS therapy. BMD was measured by DXA (Hologic). Patients were divided into 2 groups. Group I included postmenopausal women and men over 50 years (72 patients), group IIpremenopausal women and men younger 50 years (30 patients). The T-score was determined in group I and the Z-score in group II respectively. As it known the loss of bone tissue is more in trabecular bone so we assessed BMD in the spine. In 23 patients (15 women, 8 men) data were normal. 102 patients (22 men, 80 women) had osteoporosis/osteopenia. Аverage duration of GCS-therapy 6.8 years (from 2 months to 30 years).

Osteoporosis and osteopenia of the spine in rheumatic patients, treated with glucocorticosteroids